{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T19:09:11Z","timestamp":1774033751062,"version":"3.50.1"},"reference-count":36,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) are diseases driven by dysregulation of the alternative pathway (AP) complement. Current treatments of these diseases involve the use of frequent and often large doses of monoclonal antibodies, peptide inhibitors, or chemical inhibitors of complement proteins, with various limitations. In this study, we describe ectopic expression of factor D (FD) in the liver as a potential novel therapy for these indications. Unlike most plasma complement proteins, which are synthesized in the liver, FD, a serine protease in the AP, is synthesized primarily in fat tissues. Newly synthesized FD is released largely as an inactive proenzyme that requires activation by mannose-binding lectin\u2013associated serine protease 3 (MASP3) to form the mature enzyme. We found serendipitously that ectopic expression of mature FD, but not pro-FD, in the mouse liver led to C3-dependent depletion of plasma factor B (FB) and abolished AP complement activity. Coexpression of C3, FB, and mature FD in cultured Hepa1-6 cells caused intracellular FB activation and consumption, probably within the secretory vesicles where all 3 proteins may colocalize. Hepatic FD\u2013mediated local FB activation and depletion effectively prevented disease development in murine models of aHUS and C3G. Our results suggest that segregated tissue production of FD, FB, and C3, as well as FD regulation by MASP3, is necessary to prevent in situ FB activation and depletion. Ectopic expression of mature FD in the liver is an effective way to inhibit FB expression and AP complement activity, with potential therapeutic applications in diseases such as aHUS and C3G.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017828","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T20:12:06Z","timestamp":1768594326000},"page":"2024-2037","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of atypical hemolytic uremic syndrome and C3 glomerulopathy in mice by hepatic expression of factor D"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9248-3356","authenticated-orcid":false,"given":"Hangsoo","family":"Kim","sequence":"first","affiliation":[{"name":"1Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7729-2254","authenticated-orcid":false,"given":"Madhu","family":"Golla","sequence":"additional","affiliation":[{"name":"1Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6226-0807","authenticated-orcid":false,"given":"Damodar","family":"Gullipalli","sequence":"additional","affiliation":[{"name":"1Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5009-4952","authenticated-orcid":false,"given":"William","family":"Halle","sequence":"additional","affiliation":[{"name":"1Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-9515","authenticated-orcid":false,"given":"Takashi","family":"Miwa","sequence":"additional","affiliation":[{"name":"1Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9052-3694","authenticated-orcid":false,"given":"Matthew","family":"Palmer","sequence":"additional","affiliation":[{"name":"2Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8535-3601","authenticated-orcid":false,"given":"Wen-Chao","family":"Song","sequence":"additional","affiliation":[{"name":"1Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"14","key":"2026032014061029100_bib1","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","article-title":"Complement. First of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med"},{"key":"2026032014061029100_bib2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1749-6632.1983.tb18116.x","article-title":"Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3","volume":"421","author":"Pangburn","year":"1983","journal-title":"Ann N Y Acad Sci"},{"key":"2026032014061029100_bib3","doi-asserted-by":"crossref","first-page":"712572","DOI":"10.3389\/fimmu.2021.712572","article-title":"Complement factor D as a strategic target for regulating the alternative complement pathway","volume":"12","author":"Barratt","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"2026032014061029100_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/imr.13155","article-title":"Factor D","volume":"313","author":"Sekine","year":"2023","journal-title":"Immunol Rev"},{"issue":"13","key":"2026032014061029100_bib5","doi-asserted-by":"crossref","first-page":"9210","DOI":"10.1016\/S0021-9258(19)50409-4","article-title":"Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue","volume":"267","author":"White","year":"1992","journal-title":"J Biol Chem"},{"issue":"4813","key":"2026032014061029100_bib6","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1126\/science.3299705","article-title":"Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve","volume":"237","author":"Cook","year":"1987","journal-title":"Science"},{"issue":"8","key":"2026032014061029100_bib7","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.4049\/jimmunol.1701668","article-title":"Contribution of adipose-derived factor D\/adipsin to complement alternative pathway activation: lessons from lipodystrophy","volume":"200","author":"Wu","year":"2018","journal-title":"J Immunol"},{"issue":"1","key":"2026032014061029100_bib8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cell.2014.06.005","article-title":"Adipsin is an adipokine that improves beta cell function in diabetes","volume":"158","author":"Lo","year":"2014","journal-title":"Cell"},{"issue":"11","key":"2026032014061029100_bib9","doi-asserted-by":"crossref","first-page":"e178925","DOI":"10.1172\/jci.insight.178925","article-title":"Adipsin and adipocyte-derived C3aR1 regulate thermogenic fat in a sex-dependent fashion","volume":"9","author":"Ma","year":"2024","journal-title":"JCI Insight"},{"issue":"4","key":"2026032014061029100_bib10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/pro.5560050401","article-title":"Complement factor D, a novel serine protease","volume":"5","author":"Volanakis","year":"1996","journal-title":"Protein Sci"},{"issue":"1","key":"2026032014061029100_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1084\/jem.20090633","article-title":"Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor D","volume":"207","author":"Takahashi","year":"2010","journal-title":"J Exp Med"},{"key":"2026032014061029100_bib12","doi-asserted-by":"crossref","first-page":"31877","DOI":"10.1038\/srep31877","article-title":"MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked","volume":"6","author":"Dobo","year":"2016","journal-title":"Sci Rep"},{"issue":"8","key":"2026032014061029100_bib13","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.4049\/jimmunol.1201736","article-title":"Mannan-binding lectin-associated serine protease (MASP)-1 is crucial for lectin pathway activation in human serum, whereas neither MASP-1 nor MASP-3 is required for alternative pathway function","volume":"189","author":"Degn","year":"2012","journal-title":"J Immunol"},{"key":"2026032014061029100_bib14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13023-015-0345-3","article-title":"Novel MASP1 mutations are associated with an expanded phenotype in 3MC1 syndrome","volume":"10","author":"Atik","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2026032014061029100_bib15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1681\/ASN.2012060570","article-title":"Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis","volume":"24","author":"Lesher","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2026032014061029100_bib16","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1182\/blood-2016-07-728253","article-title":"Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation","volume":"129","author":"Ueda","year":"2017","journal-title":"Blood"},{"issue":"25","key":"2026032014061029100_bib17","doi-asserted-by":"crossref","first-page":"14577","DOI":"10.1073\/pnas.261428398","article-title":"Complement activation in factor D-deficient mice","volume":"98","author":"Xu","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2026032014061029100_bib18","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2008-01-134304","article-title":"Deficiency of decay-accelerating factor and complement receptor 1-related gene\/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIg","volume":"112","author":"Kim","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2026032014061029100_bib19","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.4049\/jimmunol.2200932","article-title":"MASP3 deficiency in mice reduces but does not abrogate alternative pathway complement activity due to intrinsic profactor D activity","volume":"210","author":"Gullipalli","year":"2023","journal-title":"J Immunol"},{"issue":"3","key":"2026032014061029100_bib20","doi-asserted-by":"crossref","first-page":"vlae006","DOI":"10.1093\/immhor\/vlae006","article-title":"Improved therapeutic efficacy of a bifunctional anti-C5 mAb-FH SCR1-5 fusion protein over anti-C5 mAb in an accelerated mouse model of C3 glomerulopathy","volume":"9","author":"Sato","year":"2025","journal-title":"Immunohorizons"},{"issue":"2","key":"2026032014061029100_bib21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0378-1119(91)90434-D","article-title":"Efficient selection for high-expression transfectants with a novel eukaryotic vector","volume":"108","author":"Niwa","year":"1991","journal-title":"Gene"},{"issue":"1","key":"2026032014061029100_bib22","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1038\/s41467-024-49332-8","article-title":"Transient growth factor expression via mRNA in lipid nanoparticles promotes hepatocyte cell therapy in mice","volume":"15","author":"Smith","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"2026032014061029100_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"issue":"2","key":"2026032014061029100_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0890-8508(87)90022-3","article-title":"Generation of a monoclonal antibody to mouse C5 application in an ELISA assay for detection of anti-C5 antibodies","volume":"1","author":"Frei","year":"1987","journal-title":"Mol Cell Probes"},{"issue":"3","key":"2026032014061029100_bib25","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1567-5769(00)00043-6","article-title":"Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases","volume":"1","author":"Miwa","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"2026032014061029100_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2022.06.018","article-title":"MASP-2 and MASP-3 inhibitors block complement activation, inflammation, and microvascular stasis in a murine model of vaso-occlusion in sickle cell disease","volume":"249","author":"Belcher","year":"2022","journal-title":"Transl Res"},{"key":"2026032014061029100_bib27","unstructured":"Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders. Accessed 28 January 2026. https:\/\/patents.google.com\/patent\/US10639369B2\/en."},{"issue":"12","key":"2026032014061029100_bib28","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/gt.2015.71","article-title":"Recombinant AAV-mediated in vivo long-term expression and antitumour activity of an anti-ganglioside GM3(Neu5Gc) antibody","volume":"22","author":"Piperno","year":"2015","journal-title":"Gene Ther"},{"issue":"2","key":"2026032014061029100_bib29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/19420862.2015.1008351","article-title":"Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells","volume":"7","author":"Chng","year":"2015","journal-title":"MAbs"},{"issue":"5","key":"2026032014061029100_bib30","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3390\/cells12050785","article-title":"Various AAV serotypes and their applications in gene therapy: an overview","volume":"12","author":"Issa","year":"2023","journal-title":"Cells"},{"key":"2026032014061029100_bib31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0076-6879(87)51006-0","article-title":"Liver cell lines","volume":"151","author":"Darlington","year":"1987","journal-title":"Methods Enzymol"},{"issue":"6012","key":"2026032014061029100_bib32","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.1195821","article-title":"Structures of C3b in complex with factors B and D give insight into complement convertase formation","volume":"330","author":"Forneris","year":"2010","journal-title":"Science"},{"issue":"1","key":"2026032014061029100_bib33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12468","article-title":"A journey through the lectin pathway of complement-MBL and beyond","volume":"274","author":"Garred","year":"2016","journal-title":"Immunol Rev"},{"key":"2026032014061029100_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev-med-042921-102405","article-title":"Expansion of anticomplement therapy indications from rare genetic disorders to common kidney diseases","volume":"75","author":"Miwa","year":"2024","journal-title":"Annu Rev Med"},{"key":"2026032014061029100_bib35","doi-asserted-by":"crossref","first-page":"1537974","DOI":"10.3389\/fimmu.2025.1537974","article-title":"Factor B as a therapeutic target for the treatment of complement-mediated diseases","volume":"16","author":"Kavanagh","year":"2025","journal-title":"Front Immunol"},{"issue":"25","key":"2026032014061029100_bib36","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.2174\/0929867326666191001130342","article-title":"Discovery and development of the oral complement factor D inhibitor danicopan (ACH-4471)","volume":"27","author":"Wiles","year":"2020","journal-title":"Curr Med Chem"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/2024\/2509033\/blooda_adv-2025-017828-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/2024\/2509033\/blooda_adv-2025-017828-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:06:23Z","timestamp":1774029983000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/6\/2024\/566044\/Treatment-of-atypical-hemolytic-uremic-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017828","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,24]]},"published":{"date-parts":[[2026,3,13]]}}}